Creator: Help Dementia Editorial Team
Published: 2026-04-13T09:03:37

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Fda approves sits at the center of this dementia and brain health question.

The claim that the FDA has approved an at-home dementia diagnostic test kit for $89 does not reflect current regulatory reality as of April 2026. While the FDA has recently cleared several important advances in dementia and Alzheimer’s disease detection, none of these include an at-home diagnostic kit at that price point. The actual FDA-cleared tests available today require blood draws administered by healthcare providers and cost significantly more—typically between $500 and $1,000. This distinction matters because misunderstanding what’s available could lead someone to delay proper medical evaluation or waste money on unproven alternatives.

The confusion may stem from recent legitimate FDA approvals that have genuinely advanced dementia detection. In May 2025, the FDA cleared the Lumipulse blood test, which can detect abnormal amyloid plaques associated with Alzheimer’s disease. Shortly after, in October 2025, the Elecsys pTau181 blood test received FDA approval for Alzheimer’s detection. Both represent real progress in making diagnosis more accessible than before—but they still require a healthcare provider to order the test and draw blood. Additionally, the FDA approved 23andMe’s at-home genetic test for APOE gene variants, which indicates genetic risk for Alzheimer’s disease, not current dementia diagnosis.

What Are the Actually FDA-Approved Dementia Tests Available Today?
Why Isn’t There an $89 FDA-Approved At-Home Diagnostic Test Yet?
What Recent Breakthroughs Have Actually Changed Dementia Testing?
How Do You Access These Tests If You’re Concerned About Dementia?
Beware of Unproven Tests and Marketing Claims
The Role of Lifestyle and Early Detection
Looking Forward in Dementia Detection
Conclusion

What Are the Actually FDA-Approved Dementia Tests Available Today?

The Lumipulse blood test became the first fda-cleared biomarker test that can help identify whether someone has abnormal amyloid in their brain—a hallmark of Alzheimer’s disease. This test was significant because it offered a way to detect biological signs of disease before symptoms appear or worsen, potentially opening the door to earlier intervention. However, the test costs between $500 and $1,000, and you cannot order it yourself or take it at home. Your doctor must order it, and you must go to a laboratory or healthcare facility to have blood drawn. For someone concerned about dementia risk, this is more accessible than positron emission tomography (PET) scans or cerebrospinal fluid testing, which are invasive, expensive, and available only at specialized medical centers, but it’s still far from the low-cost at-home model the $89 claim suggests. The Elecsys pTau181 test works similarly—it measures phosphorylated tau in the blood, another protein linked to Alzheimer’s pathology. Like Lumipulse, it requires a healthcare provider and a blood draw.

These blood tests represent a major shift in dementia diagnostics because they can now be done in primary care settings rather than requiring specialty neurology referrals or hospital visits. For someone without access to neurologists or specialized diagnostic centers, this is genuinely progress. But the cost and provider requirement still create barriers for some patients. The 23andMe genetic test is the only true at-home option with FDA approval related to dementia risk. You order it online, spit into a tube at home, and mail it back. The test looks for the APOE4 gene variant, which increases the risk of developing Alzheimer’s disease later in life. This costs around $200-$300 depending on promotions, but it’s crucial to understand what it does and doesn’t do: it tells you whether you carry a risk gene, not whether you have dementia now or will definitely develop it. Many people with APOE4 never develop Alzheimer’s, and some people without APOE4 do develop it.

What Are the Actually FDA-Approved Dementia Tests Available Today?

Why Isn’t There an $89 FDA-Approved At-Home Diagnostic Test Yet?

Developing and getting FDA approval for a diagnostic test—especially one that claims to diagnose dementia—requires extensive clinical validation. The test must be proven to accurately detect dementia in diverse populations, across different stages of the disease, and in real-world conditions. It must also be safe and not give false results that could cause unnecessary alarm or false reassurance. This validation process takes years and costs millions of dollars, which is why even the more recent blood tests took considerable time to develop before FDA clearance. At-home testing for something as complex as dementia is particularly challenging from a regulatory standpoint. Dementia isn’t a single biomarker you can measure like a pregnancy hormone or blood glucose. It’s a syndrome with multiple underlying causes—Alzheimer’s disease, vascular dementia, Lewy body dementia, frontotemporal dementia—each requiring different evaluations.

Some forms of dementia stem from treatable conditions like vitamin b12 deficiency or thyroid disorders. An at-home test that claims to diagnose dementia would need to either identify one specific type (like Alzheimer’s pathology) or somehow differentiate among multiple types, both of which add complexity and cost. The FDA would not approve a test that oversimplifies this and risks misdiagnosing patients. There’s also the practical limitation that diagnosis typically requires clinical assessment. A doctor needs to take a detailed history, perform cognitive testing, often obtain imaging, and sometimes conduct other evaluations. A single biomarker test—whether done at home or in a clinic—is one piece of information, not a complete diagnosis. Any legitimate $89 product claiming to diagnose dementia at home would almost certainly not meet FDA standards for safety and effectiveness, which is why such products remain unapproved.

What Recent Breakthroughs Have Actually Changed Dementia Testing?

The real breakthrough isn’t a cheaper test—it’s that dementia detection is moving from the clinic to primary care. Before the Lumipulse and Elecsys approvals, if you saw your primary care doctor with memory concerns, you’d likely be referred to a neurologist or memory clinic, often facing months-long wait lists. Now your primary care doctor can order a blood test right in their office. This democratizes access, especially for people in rural areas or those without health insurance that covers specialty care. For someone in a small town with no neurologist within 100 miles, this is transformative. The shift toward blood biomarkers also means fewer invasive procedures.

Twenty years ago, confirming Alzheimer’s disease diagnosis required a PET scan or lumbar puncture to check cerebrospinal fluid—both expensive and uncomfortable. Blood tests are simple, quick, and can be repeated if needed to monitor disease progression or treatment response. This opens possibilities for earlier intervention, since doctors can now identify Alzheimer’s pathology before significant cognitive decline occurs. The timing of these approvals—multiple major tests clearing in 2025—also reflects growing investment in Alzheimer’s therapeutics. The FDA approved lecanemab (Leqembi) in 2023 as the first Alzheimer’s disease-modifying drug, and more anti-amyloid and anti-tau treatments are in the pipeline. These drugs work best in early disease stages, so having accessible biomarker tests to identify at-risk patients is now medically urgent. The FDA is incentivizing the development of tests that can identify patients who would benefit from treatment.

What Recent Breakthroughs Have Actually Changed Dementia Testing?

How Do You Access These Tests If You’re Concerned About Dementia?

If you’re worried about memory loss, the first step is still a conversation with your primary care doctor. Describe your symptoms or concerns specifically—are you forgetting important information, getting lost in familiar places, having difficulty with familiar tasks? Your doctor will likely do some quick cognitive screening during the visit, ask about your family history of dementia or Alzheimer’s disease, and review medications that can affect cognition (some blood pressure drugs, anxiety medications, and sleep aids can impair memory). If they suspect cognitive impairment, they may order bloodwork or brain imaging. If you’re interested in knowing your genetic risk for Alzheimer’s disease—even without symptoms—the 23andMe test is accessible online. It’s direct-to-consumer, meaning you don’t need a doctor’s order.

However, genetic counseling can be helpful to interpret results. If you carry the APOE4 gene, it doesn’t mean you’ll definitely develop Alzheimer’s, but it does suggest steps like managing cardiovascular risk factors, staying cognitively active, and getting better sleep become even more important. Some people find genetic testing motivating for lifestyle changes; others find it anxiety-provoking without actionable medical interventions, so the value is personal. If you have more significant symptoms or family history, your doctor might order the blood biomarker tests—but these typically aren’t done as routine screening in asymptomatic people yet. Insurance may not cover them for that purpose, and the FDA cleared them primarily to help diagnose or assess Alzheimer’s in people with cognitive symptoms. The cost of $500-$1,000 also means they’re not practical for population-wide screening at this time.

Beware of Unproven Tests and Marketing Claims

The internet is full of dementia and “brain health” tests that claim to assess your cognitive status or predict your dementia risk. Some are based on cognitive games, others on micronutrient testing, and others on unvalidated biomarkers. None of these have FDA approval for dementia diagnosis or prediction. They may provide interesting data or feel reassuring, but they lack the clinical validation that FDA-cleared tests have undergone. Be cautious about spending money on any test claiming to diagnose or predict dementia unless it’s a recognized FDA-cleared test or is offered through a qualified healthcare provider. The $89 at-home dementia test claim you may have encountered is likely marketing for an unapproved product, a misunderstanding of what 23andMe tests actually do, or simply false information.

As of April 2026, no such product exists with FDA clearance. Scammers and unscrupulous marketers sometimes exploit fear around dementia to sell unproven products, so healthy skepticism is warranted. If someone is aggressively marketing a cheap, easy dementia test, ask for peer-reviewed evidence and FDA approval documentation. If they can’t provide it, the product isn’t legitimate. It’s also worth noting that legitimate at-home dementia diagnostic tests may eventually exist—technology and research are advancing—but they would need to go through the same rigorous FDA approval process as other tests. Until then, trusting established, FDA-cleared options or clinician-administered cognitive assessments is the safest approach.

Beware of Unproven Tests and Marketing Claims

The Role of Lifestyle and Early Detection

While we wait for more accessible diagnostic tools, what’s become clearer through research is that dementia risk isn’t inevitable. Cardiovascular health, cognitive engagement, quality sleep, social connection, physical activity, and diet all influence dementia risk. Studies suggest that managing these modifiable factors could prevent or delay cognitive decline in a significant portion of people at genetic risk. This means that even if you carry the APOE4 gene or have family history of dementia, your daily choices matter.

Early detection of cognitive changes—before they meet the threshold for dementia diagnosis—can also prompt intervention. Mild cognitive impairment (MCI) is diagnosed when someone has noticeable cognitive changes that don’t yet interfere significantly with daily function. Some people with MCI progress to dementia; others stabilize or even improve. If caught at the MCI stage through proper assessment, a doctor can identify reversible causes (medication side effects, thyroid problems, depression, sleep disorders), recommend lifestyle changes, and monitor progression more carefully. This is why bringing concerns about memory or thinking to your doctor early—rather than waiting or trying to diagnose yourself with an unproven test—remains the best approach.

Looking Forward in Dementia Detection

The rapid pace of approvals in 2025 suggests that more diagnostic tools will likely become available in coming years. Researchers are developing simpler blood tests that could be done in non-laboratory settings, potentially bringing costs down as tests become more routine and competition increases. Some labs are exploring saliva-based tests for dementia biomarkers, though these haven’t yet been FDA-cleared.

The ultimate goal is detection of pathology before symptoms appear, paired with earlier, more effective treatments. The trajectory toward more accessible, affordable testing is real—but it’s happening through legitimate research and FDA review, not through shortcuts. By the time an affordable at-home diagnostic test for dementia reaches the market with FDA approval, it will have been tested extensively to ensure it actually works and doesn’t harm people through misdiagnosis. Until then, the approved options available today—through your doctor or through 23andMe for genetic risk assessment—represent the evidence-based choices for anyone concerned about dementia.

Conclusion

There is currently no FDA-approved at-home dementia diagnostic test kit priced at $89. The actual breakthroughs in dementia detection—Lumipulse and Elecsys blood tests—are moving toward primary care but still require a healthcare provider order and blood draw, with costs between $500 and $1,000. The only approved at-home test is 23andMe’s genetic risk assessment for the APOE4 gene, which indicates risk, not current diagnosis, and costs around $200-$300. Any product marketed as a cheap, easy, at-home dementia diagnostic test should be viewed with skepticism unless it comes with documented FDA approval and peer-reviewed evidence.

If you’re concerned about cognitive changes, start with your primary care doctor. They can assess your symptoms, review your history, and order appropriate testing if needed. If you want to understand your genetic risk, 23andMe is a legitimate option. And if you have symptoms concerning for dementia, the blood biomarker tests available through your doctor now offer a way to check for Alzheimer’s pathology that’s far more practical than PET scans or lumbar punctures. The goal is always to catch cognitive changes early, identify any treatable causes, and begin interventions—lifestyle or medical—that can help preserve brain health and function.